Table 1. Histological diagnosis for glioma grading in KSNO, NCCN, and EANO guideline.

KSNO		NCCN		EANO
Essential		Essential		Essential
	- Codeletion of 1p/19 test		- Codeletion of 1p/19 test		- IDH mutation test
	- IDH mutation test		- IDH mutation test		- ATRX mutation test
	- ATRX mutation test		- ATRX mutation test		- Codeletion of 1p/19 test
	- MGMT promoter methylation		- MGMT promoter methylation		- TERT promoter mutation
Consider glioblastoma features		Additional			- EGFR amplification
	- TERT promoter mutation		- NTRK gene fusion		- Chromosome 7 gain and 10 loss
	- EGFR amplification		- BRAF V600E		- H3.3 G34R/V
	- Chromosome 7 gain and 10 loss		- mTOR mutation	Additional
			- MEK mutation		- CDKN2A/B
					- H3K27M mutation

ATRX, ATP-dependent helicase; BRAF, V-Raf murine sarcoma viral oncogene homolog B1; CDKN2A, cyclin dependent kinase inhibitor 2A; EGFR, epidermal growth factor receptor; IDH, isocitrate dehydrogenase; MEK, methyl ethyl ketone; mTOR, mammalian target of rapamycin; NTRK, neurotrophic tyrosine receptor kinase; TERT, telomerase reverse transcriptase